Blocking Cancer Signaling Leads to Discovery of New Tumor-Promoting Pathway 11 | GENengnews.com "Since we were genetically deleting the ERK1/2 pathway, we expected to see less cell proliferation," explained co-lead study author Petrus R. de Jong, M.D., Ph.D., translational scientist at Sanford Burnham Prebys Medical Discovery Institute. "Instead, the opposite occurred. There was more cell growth and loss of organization within the cells." The exciting part of this new study is investigators found that treating both ERK1/2 and the compensatory pathway ERK5 concomitantly with a combination of drug inhibitors ADDITIONAL CONTENT Immuno-Oncology Infographic Download this infographic to learn how continuous live-cell analysis enables a new range of non-invasive phenotypic measurements for immuno-oncology research. Download Now Rafe Swan/Getty Images A n international research team lead by scientists at the University of California San Diego (UCSD) School of Medicine uncovered some surprising results while investigating a potential therapeutic target for the ERK1 and two pathways. These signaling pathways are widely expressed and known to drive cancer growth in one-third of patients with colorectal cancer (CRC). The UCSD team found that an alternative pathway immediately emerges when ERK1/2 is halted, thus allowing tumor cell proliferation to continue.https://www.essenbioscience.com/en/forms/immuno-oncology-infographic-request/ http://www.GENengnews.com